SCHEMBL2497495

SCHEMBL2497495

OC=CCc1nnn[nH]1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9643654 0.76 GABRR1 (0.34)
SCHEMBL1956841 0.73
SCHEMBL3073811 0.67
SCHEMBL3872946 0.64 ALDH1A1 (0.33)
SCHEMBL10629678 0.63 ALDH1A1 (0.48)
SCHEMBL595749 0.62
SCHEMBL16752719 0.62 L3MBTL1 (0.36)
SCHEMBL10641491 0.62 L3MBTL1 (0.36)
Hydrochloric Acid SCHEMBL13718807 0.62
Hydrochloric Acid SCHEMBL7440333 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2479175-A1 Compounds and methods for treating dyslipidemia Eli Lilly and Company (US) 2012-07-25 EP disclosed
EP-1761522-B1 COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA LILLY CO ELI (US) 2011-10-12 EP disclosed
US-7786108-B2 Compounds and method for treating dyslipidemia ELI LILLY AND COMPANY (US) 2010-08-31 US disclosed
US-20100204207-A1 Compounds and Methods for Treating Dyslipidemia CHEN XINCHAO 2010-08-12 US disclosed
US-7470705-B2 e.g. Cis-4-[acety1-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-ethyl-6-methoxy-3,4-dihydro-2H- [1,5]naphthyridine-1-carboxylic acid isopropyl ester; cholesterol ester transfer protein (CETP) inhibitors; increasing plasma HDL- cholesterol, decreasing plasma LDL- cholesterol; atherosclerosis ELI LILLY AND COMPANY (US) 2008-12-30 US disclosed
US-20080269284-A1 Compounds and Methods for Treating Dyslipidemia ELI LILLY AND COMPANY (US) 2008-10-30 US disclosed
US-20070244095-A1 S)-(3,5-Bistrifluoromethylbenzyl)-(1-cyclopentylmethyl-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-yl)-(2-methyl-2H-tetrazol-5-yl)amine, for treating and/or preventing diseases related to abnormal cholesterol ester transfer protein activity such as atherosclerosis ELI LILLY AND COMPANY 2007-10-18 US disclosed
US-20070173526-A1 Compounds and methods for treating dyslipidemia ELI LILLY AND COMPANY (US) 2007-07-26 US disclosed
EP-1761521-A1 COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA ELI LILLY AND COMPANY (US) 2007-03-14 EP disclosed
EP-1735320-A1 COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA ELI LILLY AND COMPANY (US) 2006-12-27 EP disclosed
WO-2006012093-A1 COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA ELI LILLY AND COMPANY (US) 2006-02-02 WO disclosed
WO-2005097806-A1 COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA ELI LILLY AND COMPANY (US) 2005-10-20 WO disclosed
EP-0305085-B1 LEUKOTRIENE ANTAGONISTS ELI LILLY AND COMPANY (US) 1993-07-28 EP disclosed
US-4820722-A TREATING ALLERGIES, ASTHMA ELI LILLY AND COMPANY (US) 1989-04-11 US disclosed
EP-0305085-A1 Leukotriene antagonists ELI LILLY AND COMPANY (US) 1989-03-01 EP disclosed